Altimmune ALT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | $41K+105% | $20K-61.5% | $20K-95.1% | $20K-95.1% | ||
| $66.8M-12.8% | $66.43M-19.2% | $67.8M-14.6% | $72.65M-6.8% | $76.57M+9.3% | ||
| $30.16M+39.3% | $28.1M+34.0% | $22.68M+12.2% | $21.74M+10.1% | $21.65M+14.4% | ||
| $96.95M-1.3% | $94.53M-8.4% | $90.48M-19.2% | $94.39M-14.3% | $98.21M-3.1% | ||
| -$96.92M+1.3% | -$94.49M+8.4% | -$90.46M+19.2% | -$94.37M+14.0% | -$98.19M+2.7% | ||
| $2.7M+29,933% | $1.64M+18,078% | $761K+7,510% | $272K+724% | $9K-73.5% | ||
| $5.84M-19.7% | $5.72M-29.6% | $5.87M-30.2% | $5.94M-28.9% | $7.27M-11.3% | ||
| -$91.08M-0.2% | -$88.77M+6.6% | -$84.6M+18.3% | -$88.43M+12.7% | -$90.92M— | ||
| —— | —— | —— | —— | —— | ||
| -$91.08M-0.9% | -$88.09M+7.3% | -$83.92M+18.9% | -$87.75M+13.4% | -$90.24M+2.7% | ||
| -$0.92+27.0% | -$1.00+25.4% | -$1.07+31.8% | -$1.18+28.0% | -$1.26+21.7% | ||
| -$96.81M+1.2% | -$94.38M+8.3% | -$90.34M+19.1% | -$94.24M+14.3% | -$98.03M+3.7% | ||
| -$96.92M+1.3% | -$94.49M+8.4% | -$90.46M+19.2% | -$94.37M+14.0% | -$98.19M+2.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Altimmune's revenue?
- Altimmune (ALT) generated $41.0K in revenue over the trailing twelve months, up 105.0% year over year.
- Is Altimmune profitable?
- Altimmune is not currently profitable: it reported a net loss of $91.1M over the trailing twelve months, a -214861.0% net margin.
- What is Altimmune's earnings per share?
- Altimmune's diluted EPS over the trailing twelve months is $-0.92.
- Where does Altimmune's income statement data come from?
- Every line is extracted from Altimmune's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
